Orthocell Ltd (ASX:OCC) chair John Van Der Wielen joins Proactive’s Tylah Tully to discuss the company’s latest milestone. OCC has officially entered the Canadian market with the first sale of its Striate+™ product, following regulatory approval from Health Canada in July 2024.
Striate+ is used in dental guided bone and tissue regeneration, and this milestone marks a key step in the company’s global expansion strategy. The Canadian regenerative medicine market is valued at A$60 million, contributing to the global market opportunity of more than A$1 billion for Striate+.
Orthocell’s partner BioHorizons facilitated the swift transition from regulatory approval to sales, further validating the high quality of Striate+ and the effectiveness of the partnership. The company has reported a 98.6% success rate from post-market clinical studies of Striate+, which has already gained significant traction in other major markets including the USA, UK, EU and Australia.
Orthocell expects to expand into the Singapore and Brazil markets within the next six to 12 months. The company recorded A$6.76 million in revenue for FY24, reflecting a 30% increase year-on-year, and maintains a strong cash position of A$20.6 million.
#ProaactiveInvestors #Orthocell #ASX #BioHorizons #StriatePlus #DentalRegeneration #HealthCanada #RegenerativeMedicine #GlobalExpansion #Canada #Brazil #Singapore #MedicalDevices #BoneRegeneration #TissueRegeneration #MarketGrowth #RevenueGrowth #ClinicalSuccess #MedTech #MedicalInnovation #DentalImplants #HealthcareMarket #OrthocellExpansion
#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
Categories
Orthocell enters Canadian market with Striate+ sales [Video]
